Completed PHASE1 INTERVENTIONAL NCT00445419

Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides

A Phase I Single-blind Randomised Placebo Controlled Dose Escalating Study of One Virosome Formulated CD4 and Two Virosomes Formulated CD8 Hepatitis C Virus (HCV) Vaccine Components (PEV2A and PEV2B) Administered to Healthy Adult Volunteers

Sponsor: Pevion Biotech Ltd

Conditions Chronic Hepatitis C

Interventions PEV2A PEV2B

Updated 5 times since 2017 Last updated: Feb 5, 2010 Started: Dec 31, 2006 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Chronic Hepatitis C and is currently completed. Pevion Biotech Ltd leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pevion Biotech Ltd

Data source: Pevion Biotech Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lausanne, Switzerland